All In Biotech

Drug Trial Radar · NCT07929805

ACT201 Injection in Participants With Chronic Hepatitis B (CHB) on Nucleos(t)Ide Analog Therapy - Phase Ib

A Multicenter, Randomized, Open-label Phase Ib Clinical Trial to Evaluate the Safety and Efficacy of ACT201 Injection in Participants With Chronic Hepatitis B (CHB) Receiving Nucleos(t)Ide Analog Therapy

Last checked: Nov 20, 2026Latest source record: Nov 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

40

Planned (sponsor's estimate)

Start

Nov 20, 2026

Primary completion

Feb 2027

Study completion Dec 2027

Sponsor

Sponsor type
Industry
Collaborators
The First Affiliated Hospital of Xiamen University
First posted
Nov 10, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multicenter, randomized, open-label, parallel-controlled Phase Ib clinical trial. It aims to evaluate the safety and preliminary efficacy of ACT201 Injection combined with standard therapy (PegIFNα, NA) in participants with chronic hepatitis B who are receiving NA treatment. A total of 40 participants with chronic hepatitis B will be enrolled. Eligible participants should have stable NA treatment, HBV DNA \< 100 IU/mL, negative HBeAg, and HBsAg ≤ 100 IU/mL. They will be randomized into four treatment groups at a 1:1:1:1 ratio.

Conditions

  • Chronic Hepaititis B

Interventions

  • ACT201 InjectionDrug

    Subcutaneous injection per assigned dose group; treatment duration shall follow the study protocol.

  • ACT201 InjectionDrug

    Subcutaneous injection per assigned dose group; treatment duration shall follow the study protocol.

  • ACT201 InjectionDrug

    Subcutaneous injection per assigned dose group; treatment duration shall follow the study protocol.

  • ACT201 InjectionDrug

    Subcutaneous injection per assigned dose group; treatment duration shall follow the study protocol.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety: number of participants with adverse event (AE), serious adverse events (SAE) and clinically significant examination results. Assessments include vital signs, physical examinations, laboratory tests, and 12-lead electrocardiograms (ECGs).Time frame: throughout the full study period,an average of 38 weeks

Locations

4 sites in 1 country. Site status is shown where the registry gives one.

  • Beijing Ditan Hospital, Capital Medical University

    Beijing, China

  • Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology

    Wuhan, China

  • The Second Affiliated Hospital of Xi'an Jiaotong University

    Xi'an, China

  • The First Affiliated Hospital of Xiamen University

    Xiamen, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.